*  METHODS AND FORMULATIONS FOR REDUCING AMPHOTERICIN B TREATMENT SIDE EFFECTS - Patent application
... formulation that comprises a polyene active ingredient that includes amphotericin B, wherein the amphotericin B compound is ... providing a formulation that comprises a polyene active ingredient that includes amphotericin B, wherein the amphotericin B ... Samples of each amphotericin formulation are diluted in about 1.0 mL DMSO, then further diluted with about 5 mL methanol. A 400 ... Amphotericin B Amphotericin B (generic) 1958 deoxycholate (AmBD) Amphotericin B lipid ABELCET ® The Liposome 1995 complex (ABLC ...
  http://www.patentsencyclopedia.com/app/20110152211
*  Coccidioidomycosis
Data regarding lipid formulations of amphotericin B are limited, but these formulations are likely as effective. ... Certain specialists add triazole to amphotericin B therapy and continue triazole once amphotericin B is stopped (BIII). ... Clin Infect Dis 2005;41:1217-23.). Most experience has been with the deoxycholate formulation using 0.7-1.0 mg/kg daily as an ... Therapy with amphotericin B should continue until clinical improvement is observed. Certain specialists would use a triazole ...
  http://hivinsite.ucsf.edu/hiv?page=md-agl-cocc
*  Cocci | Invasive Mycoses | Adult and Adolescent Opportunistic Infection | AIDSinfo
There are no reported studies that have used lipid formulations of amphotericin B for the treatment of coccidioidomycosis, but ... Lipid formulation amphotericin B 3-5 mg/kg IV daily (AIII), or ... Amphotericin B deoxycholate 0.7-1.0 mg/kg IV daily (AII). *Use ... to amphotericin B therapy and continue the triazole once amphotericin B is stopped (BIII) ... A dose of 400 mg twice daily of the older liquid formulation of posaconazole has been used (BII),22 but the current extended- ...
  https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/335/cocci
*  Search of: aspergillosis - List Results - ClinicalTrials.gov
Drug: Comparator: amphotericin B. *Drug: Comparator: lipid formulation of amphotericin B and/or azole ... Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis. *Aspergillosis. *Drug: nebulised liposomal ... Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia. * ... Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation. *Invasive ...
  https://clinicaltrials.gov/ct2/results?term=aspergillosis&Search=Search
*  Search of: 'Aspergillosis' - List Results - ClinicalTrials.gov
Drug: Comparator: amphotericin B. *Drug: Comparator: lipid formulation of amphotericin B and/or azole ... Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis. *Aspergillosis. *Drug: nebulised liposomal ... Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis. *Aspergillosis ... Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of ...
  https://clinicaltrials.gov/ct2/results?cond=%22Aspergillosis%22&show_rss=Y
*  Amphotericin B Cholesteryl Sulfate Complex Injection Drug Shortage Notice - Drugs.com
Current drugs shortage notification for Amphotericin B Cholesteryl Sulfate Complex Injection including reason for shortage, ... The shortage of amphotericin b cholesteryl sulfate lipid complex is not affecting other amphotericin formulations. ... Alkopharma was the sole supplier of amphotericin b cholesteryl sulfate lipid complex. The company's phone is no longer in ... Amphotericin B Cholesteryl Sulfate Complex Injection. Last Updated: October 20, 2014. Status: Discontinued ...
  https://www.drugs.com/drug-shortages/amphotericin-b-cholesteryl-sulfate-complex-injection-894
*  ISMP Quarterly Action Agenda
Problem: Mix-ups have occurred between liposomal and conventional formulations of IV amphotericin B. Conventional amphotericin ... Mix-ups between various formulations of amphotericin B (21) ... Restrict the preparation and dispensing of amphotericin B to ... Reccomendation:Communicate orders using both the proprietary and complete generic name (e.g., AMBISOME [amphotericin B ... Dose checking alerts should be utilized in computer systems for both liposomal and conventional formulations. Consider adding a ...
  https://www.ismp.org/Newsletters/acutecare/articles/A1Q13Action.asp
*  Candidiasis
Amphotericin B has decreased activity against biofilms; liposomal Amphotericin formulations are more active. ... Amphotericin B has decreased activity against biofilms; liposomal Amphotericin formulations are more active. ... Lipid formulations of Amphotericin B (LFAmBs) (IV). (3-5 in guidelines) 5 mg/kg/day. Increased daily dose tolerated & less ... The lipid formulations of Amphotericin B (LFAmBs) are less nephrotoxic; however, as a result they do not penetrate the kidneys ...
  http://www.endocrinologyadvisor.com/pediatrics/candidiasis/article/623590/
*  Candidiasis (Candidosis) - ONA
Lipid formulation amphotericin B (3-5 mg/kg daily) is an alternative if there is resistance to a more desired medication or ... Amphotericin lozenges (10mg) or suspension (100mg/ml) 4 times a day for 14-21 days is effective as well. Miconazole gel 2% 2.5 ... Prolonged use of systemic antifungals requires monitoring of the liver (azoles) and kidneys (amphotericin). It is important to ... may be more effective than fluconazole or amphotericin B. ... as there is significant toxicity with using amphotericin B.. ...
  http://www.oncologynurseadvisor.com/dermatology/candidiasis-candidosis/article/593635/
*  Frontiers | Effect of the Ethyl Acetate Fraction of Eugenia uniflora on Proteins Global Expression during Morphogenesis in...
Hamill, R. J. (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 73, 919-934. doi: ... In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the ... such as amphotericin B, which causes renal toxicity (Hamill, 2013). Therefore, the investigation of natural products and their ... because others have found the same effect with amphotericin B and this is still a very broad spectrum and highly effective ...
  https://www.frontiersin.org/articles/10.3389/fmicb.2017.01788/full
*  Fungemia - Wikipedia
The lipid formulation amphotericin B is a reasonable alternative if there is limited antifungal availability, antifungal ...
  https://en.wikipedia.org/wiki/Fungemia
*  US5908869A - Propofol compositions containing edetate - Google Patents
A comparative review of conventional and lipid formulations of amphotericin B. US6177477B1 (en) 2001-01-23. Propofol ... Morinda Citrifolia-Based Formulation 5-LOX And 15-LOX JP2005528390A (en) * 2002-04-10. 2005-09-22. コンフォーマ・セラピューティクス・コーポレイション ... Drug formulations having long and medium chain triglycerides US20040192761A1 (en) * 2003-03-25. 2004-09-30. Palu Afa Kehaati. ... Ansamycins formulation and manufacturing, as well as methods of use thereof US7550155B2 (en) * 2002-07-29. 2009-06-23. ...
  https://patents.google.com/patent/US5908869A/en
*  3 Companies Spearheading the Antibiotics Space in 2018 - 24/7 Wall St.
Matinas has completed Phase 2 trials showing that its formulation of amphotericin B all but eliminates poisonous side effects. ... Insmed's formulation known as ALIS (for amikacin liposome inhalation suspension) encases the antibiotic in a lipid cushion for ... The only antifungal known to fit the profile is amphotericin B, a poisonous antifungal only taken as a last resort due to ... The same technology driving amphotericin B is being used in amikacin, the selfsame drug that succeeded in Phase 3 for Insmed, ...
  https://247wallst.com/healthcare-business/2017/11/10/3-companies-spearheading-the-antibiotics-space-in-2018/amp/
*  Fungal Pneumonia: Overview of Fungal Pneumonia, Risk Factors, Epidemiology of Fungal Pneumonia
Amphotericin B is available in a variety of formulations. Conventional amphotericin B injection contains amphotericin B and ... Lipid formulations of amphotericin B have at least equal efficacy but less toxicity compared with amphotericin B desoxycholate ... Lipid formulations of amphotericin B have at least equal efficacy but less toxicity compared with amphotericin B desoxycholate ... Other formulations, however, are starting to replace amphotericin B because of their ease of use (oral formulations) and lower ...
  https://emedicine.medscape.com/article/300341-overview
*  Sporotrichosis - Wikipedia
Lipid formulations of amphotericin B are usually recommended instead of amphotericin B deoxycholate because of a better adverse ... Amphotericin B. This antifungal medication is delivered intravenously. Many patients, however, cannot tolerate Amphotericin B ... Amphotericin B can be used for severe infection during pregnancy. For children with disseminated or severe disease, ... In case of sporotrichosis meningitis, the patient may be given a combination of Amphotericin B and 5-fluorocytosine/Flucytosine ...
  https://en.wikipedia.org/wiki/Sporotrichosis
*  Fibers | Free Full-Text | The Significance and Insignificance of Carbon Nanotube-Induced Inflammation | HTML
Prajapati, V.K.; Awasthi, K.; Yadav, T.P.; Rai, M.; Srivastava, O.N.; Sundar, S. An oral formulation of amphotericin b attached ... Price, R.L.; Waid, M.C.; Haberstroh, K.M.; Webster, T.J. Selective bone cell adhesion on formulations containing carbon ...
  http://www.mdpi.com/2079-6439/2/1/45/htm
*  Cutaneous Mucormycosis (Mucormycosis/Zygomycetes) - The Clinical Advisor
All formulations of amphotericin B are administered via the intravenous route. Amphotericin B deoxycholate is associated with ... or lipid formulations of amphotericin B. Generally, such high doses of conventional amphotericin B cannot be tolerated for very ... The lipid formulations of amphotericin B are less likely to cause these toxicities, especially renal insufficiency. ... Conventional amphotericin B, dosed at 1.0-1.5mg/kg/day, is the preferred treatment. Alternatively, lipid-based amphotericin B ...
  http://www.clinicaladvisor.com/dermatology/cutaneous-mucormycosis-mucormycosiszygomycetes/article/589617/
*  Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis - Full Text View - ClinicalTrials.gov
Any course of systemic treatment with amphotericin B (conventional or lipid formulation) or itraconazole should have been ... Drug Information available for: Amphotericin B Voriconazole Liposomal Amphotericin B Genetic and Rare Diseases Information ... to conventional or a lipid formulation of amphotericin B.. No subjects who are receiving and cannot discontinue the following ... Amphotericin B in the Treatment of Invasive Aspergillosis. The safety and scientific validity of this study is the ...
  https://clinicaltrials.gov/show/NCT00001646?order=17
*  Respiratory Failure due to Possible Donor-Derived Sporothrix schenckii Infection in a Lung Transplant Recipient
Clinical and radiographic responses occurred after initiation of amphotericin B lipid formulation. Conclusion. We believe that ... Our patient responded well to amphotericin induction therapy followed by maintenance therapy with itraconazole. The ...
  https://www.hindawi.com/journals/criid/2015/925718/abs/
*  Amphotericin B - Wikipedia
As the original formulation of amphotericin, it is often referred to as "conventional" amphotericin. In order to improve the ... They are more expensive than amphotericin B deoxycholate. AmBisome (LAMB) is a liposomal formulation of amphotericin B for ... Two amphotericins, amphotericin A and amphotericin B, are known, but only B is used clinically, because it is significantly ... Amphotericin B alone is insoluble in normal saline at a pH of 7. Therefore, several formulations have been devised to improve ...
  https://en.wikipedia.org/wiki/Amphotericin_B
*  Blastomycosis - Wikipedia
Patients who cannot tolerate deoxycholate formulation of Amphotericin B can be given lipid formulations. Fluconazole has ... Amphotericin B is considerably more toxic, and is usually reserved for immunocompromised patients who are critically ill and ... excellent CNS penetration and is useful where there is CNS involvement after initial treatment with Amphotericin B. Mortality ...
  https://en.wikipedia.org/wiki/Blastomycosis
*  Goliath heron - Wikipedia
Bonar, Christopher J.; Lewandowski, Albert H. (2004). "Use of a Liposomal Formulation of Amphotericin B for Treating Wound ... "Use of a Liposomal Formulation of Amphotericin B for Treating Wound Aspergillosis in a Goliath heron (Ardea goliath)". Journal ...
  https://en.wikipedia.org/wiki/Goliath_heron
*  Amphotericin B lipid complex: treatment of invasive fungal infections | TCRM
Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate PH ChandrasekarDivision of Infectious Diseases, Department of Internal Medicine, Wayne State University, Karmanos Cancer Institute, Detroit, MI, USAAbstract: Amphotericin B lipid complex (ABLC) was introduced in the late 1990s as a less toxic alternative to amphotericin B (AmB) deoxycholate. ABLC is a safe and effective broad-spectrum drug in the treatment of invasive fungal infections in patients with infection refractory to AmB deoxycholate or in patients intolerant of the same formulation. The drug has not been rigorously evaluated for primary therapy. Recent availability of several newer potent and safe drugs has sharply curtailed the use of potentially nephrotoxic ABLC. However, AmB lipid complex is likely to ...
  https://www.dovepress.com/amphotericin-b-lipid-complex-treatment-of-invasive-fungal-infections-i-peer-reviewed-article-TCRM-recommendation1
*  Gene amplification in amphotericin B-resistant Leishmania tarentolae.
Two Leishmania tarentolae cells were selected step by step for resistance to the polyene antibiotic amphotericin B, a second-line drug against the parasite Leishmania. One of the mutants was cross-resistant to ketoconazole. DNA amplification was observed in both mutants. The amplicons were extrachromosomal circles and were derived from different chromosomes. In one mutant the circle was unusually stable as it remained within the cell despite numerous passages in the absence of the drug. A circumstantial link between the copy number of amplicons and the resistance levels was established. Gene transfection experiments indicated that the link between the locus amplified and the resistance levels was not straightforward and possibly several mutations act together to lead to amphotericin B resistance. Copyright 2001 Elsevier Science (USA).. ...
  http://www.ketoconazole.com/news_article.html?tx_ttnews%5Bpointer%5D=6&tx_ttnews%5Btt_news%5D=527&tx_ttnews%5BbackPid%5D=77&no_cache=1
*  Cryptococcosis | Pediatric OI Prevention and Treatment Guidelines | AIDSinfo
In patients who cannot tolerate flucytosine (or if flucytosine is not available), amphotericin B deoxycholate (or its liposomal preparation) with or without fluconazole can be used for initial therapy (BI*). In a randomized Phase II trial in HIV-infected adolescents and adults, amphotericin B deoxycholate plus high-dose fluconazole (800 mg daily) was found to be well tolerated and with a trend toward better outcome at days 42 and 70, compared with amphotericin B deoxycholate alone.25 Studies are needed to further validate the use of this combination. In another study 80 HIV-seropositive, antiretroviral (ARV)-naive adults presenting with cryptococcal meningitis were randomized to 4 treatment arms of 2-week duration: group 1, amphotericin B (0.7-1 mg/kg) and flucytosine (25 mg/kg 4 times daily); group 2, amphotericin B (0.7-1 mg/kg) and ...
  https://aidsinfo.nih.gov/guidelines/html/5/pediatric-oi-prevention-and-treatment-guidelines/400/cryptococcosis
*  Amphotericin B Lipid Complex injection 10,25,50 & 100 mg Supplier,Exporter ,Wholesaler Price India | 3S Corporation
It is used in the treatment of fungal infections. 3s corporation is Exporter ,Wholesaler for Amphotericin B Lipid Complex injection10,25,50 & 100 mg in India.
  http://www.3scorporation.com/products/amphotericin-b-lipid-complex-injection-102550-100-mg/
*  The post antifungal effect of nystatin and amphotericin B on Candida Species in different media - UQ eSpace
Shu, M, Ellepola, ANB and Samaranayake, LP (2000). The post antifungal effect of nystatin and amphotericin B on Candida Species in different media. In: Journal of Dental Research. , , (479-479). . ...
  https://espace.library.uq.edu.au/view/UQ:322889
*  To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar - Full Text...
Visceral Leishmaniasis, which is progressive and fatal if not treated, is an insidious, chronic disease that is characterized by irregular fever, anorexia, weight loss, cough, gross enlargement of the spleen and liver, mild anemia and emaciation. This may be preceded by rigors and vomiting. If untreated, Kala-azar, which is the most severe form of Leishmaniasis, has a mortality rate of nearly 100%.. The goal of the project is to establish that a single dose of AMPHOMUL® can be used to achieve a Definitive cure for Visceral Leishmaniasis leading to a short course therapy. The project will also seek to establish that AMPHOMUL ® is safe, at least as effective and more affordable than current treatment, and is without the risk of drug resistance.. The trial is a Prospective, Multicentric, Randomized, Two Arm, Open label Phase III study to Assess Efficacy and Safety of Infusion of Amphomul® (Amphotericin B Emulsion) as Compared to Liposomal ...
  https://clinicaltrials.gov/ct2/show/NCT00876824
*  Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of...
Note: This work was presented in part at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 31 January 2000.. Acknowledgments: The authors thank Deanne Fuller, Dr. Tom Davis, and Ann LeMonte for laboratory work; Estella C. Wheatley for preparation of the manuscript; and Cynthia R. Flanigan for help with the management of the data over the course of the clinical trial.. Grant Support: In part by a grant from the National Institute of Allergy and Infectious Diseases to the Mycoses Study Group (contract NO1-A1-15802) and by a grant from the National Center for Research Resources, General Clinical Research Center (contract MO1-RR02558) to participating centers, and by Gilead Sciences, Inc. (formerly NeXstar Pharmaceuticals).. Requests for Single Reprints: Philip C. Johnson, MD, University of Texas-Houston Medical School, Division of General Medicine, 6431 Fannin, MSB 1.122, Houston, TX 77030; e-mail, Philip.C.Johnson@uth.tmc.edu.. Current Author Addresses: ...
  http://annals.org/aim/fullarticle/715437/safety-efficacy-liposomal-amphotericin-b-compared-conventional-amphotericin-b-induction
*  amphotericin B deoxycholate loaded cubosomal nanoparticles mixture
Page contains details about amphotericin B deoxycholate loaded cubosomal nanoparticles mixture . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.com
  http://nano.nature.com/nano/GR-M2849136
*  Biology-Online • View topic - The Fiber Disease
A Double-Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients [Bowden R et al. CID 2002;35:359]: The authors report a multicenter randomized, double-blind trial of Amphotec (ABCD) in a dose of 6 mg/kg/day vs. Amphotericin B in a dose of 1.0-1.5 mg/kg/day for treatment of invasive aspergillosis in 174 patients. The diagnosis was considered "proven" if there was a compatible clinical illness and detection of aspergillus by stain or culture from a normally sterile site, or proven with histopathology; it was "probable" if pulmonary with typical clinical and x-ray findings combined with two positive sputum cultures or a positive stain or culture from a BAL. Of the 174 participants, 88 were given ABCD and 86 were given Amphotericin B. Most of the patients had a ...
  http://www.biology-online.org/biology-forum/about1958-3744.html?hilit=Inlet
*  Amphotericin B | Pathway Medicine
Amphotericin B binds to ergosterol in the cell wall of fungi and generates pores which permeabilize the cell wall. Deranges permeability of the fungal cell wall, especially to electrolytes, probably results in fungal cell death. At higher concentrations Amphotericin B begins binding cholesterol in the mammalian cell membrane and accounts for the drug's adverse effects ...
  http://pathwaymedicine.org/Amphotericin-B
*  Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex - Full Text View - ClinicalTrials.gov
This is a randomized, open label, prospective study of ABLC at 5.0 and 10.0 mg/kg/d for treatment of patients with cryptococcal meningitis. Patients will be randomly assigned in a 1:1 ratio to receive 5.0 or 10.0 mg/kg/d of ABLC as induction therapy for cryptococcal meningitis. Patients receiving 10 mg/kg/d doses will be treated with ABLC for 7 days whereas patients receiving ABLC at 5.0 mg/kg/d will receive 14 days of ABLC therapy. After completion of induction therapy subjects will receive long-term fluconazole maintenance therapy at the discretion of the treating physician. The study will be conducted at the Washington Hospital ...
  https://clinicaltrials.gov/show/NCT01656382?order=132
*  Low-Dose Liposomal Amphotericin Effective in Aspergillosis | Cancer Network | The Oncology Journal
NEW ORLEANS-High doses of liposomal amphotericin B are no more effective than low doses in the treatment of invasive aspergillosis in neutropenic patients, European researchers reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1
  http://www.cancernetwork.com/articles/low-dose-liposomal-amphotericin-effective-aspergillosis
*  MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044) - Full Text View -...
This study is a double-blind, randomized study of MK0991 versus liposomal amphotericin B in the empirical treatment of pediatric patients (ages 2 through 17 years) who have an absolute neutrophil count (ANC) below 500/microliter and who have fever despite broad antibiotic coverage. Such patients would be candidates for empirical therapy with an intravenous anti-fungal agent ...
  https://clinicaltrials.gov/ct2/show/NCT00082537
*  IDEALS @ Illinois: Synthesis-enabled understanding of the mechanism of action of amphotericin B and the development of...
The polyene macrolide amphotericin B (AmB) remains a critically vital antifungal as the last line of defense against a wide range of life-threatening fungal pathogen. Despite its clinical usage for over half a century, AmB has evaded the development of clinically relevant microbial resistance. AmB has been shown to form ion channels similar to that of their protein counterparts, which has led to the proposal that AmB kills yeast cells via membrane permeabilization. The capacity for ion channel formation and cytotoxicity of AmB are thought to be dependent upon membranous sterol, but the role of sterols in this mechanism and whether membrane permeabilizaton and biological activity are even linked has remained unclear. Thus, the complete understanding of the mechanism of action of AmB would enable the development of new antifungals with an improved therapeutic index, as well as guide the pursuit of new antimicrobials that evade resistance. To elucidate the operative mechanism, ...
  https://www.ideals.illinois.edu/handle/2142/92874
*  Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal...
Time to a positive clinical response is defined as the time from the first dose to the day during the treatment period that a positive clinical response (defined as a complete response or partial response) is observed for the first time, assessed by the Investigator.. Complete Response is defined as the resolution of all attributable signs related to fungal infection, if present at baseline and Partial Response is defined as improvement in attributable signs related to the fungal infection, if present at baseline.. Infants without positive responses and who survived were censored at one day post the end of treatment. Infants without positive responses who died before completing the treatment period, or were lost to follow-up during the treatment were censored at their death or last contact day. ...
  https://clinicaltrials.gov/ct2/show/study/NCT00815516
*  Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal...
Time to a positive clinical response is defined as the time from the first dose to the day during the treatment period that a positive clinical response (defined as a complete response or partial response) is observed for the first time, assessed by the Investigator.. Complete Response is defined as the resolution of all attributable signs related to fungal infection, if present at baseline and Partial Response is defined as improvement in attributable signs related to the fungal infection, if present at baseline.. Infants without positive responses and who survived were censored at one day post the end of treatment. Infants without positive responses who died before completing the treatment period, or were lost to follow-up during the treatment were censored at their death or last contact day. ...
  https://clinicaltrials.gov/show/NCT00815516
*  Amphotericin B - Essay about Antifungals, RTT, Rare diseases
This 321 word essay is about Antifungals, RTT, Rare diseases, Amphotericin B, Mycosis, Fungistatics, Candidiasis, Tinea, Dermatophytosis. Read the full essay now!
  https://digitalessays.com/essays/amphotericin-b
*  Amphotericin b liposomal Drug Interactions - Drugs.com
193 medications are known to interact with amphotericin b liposomal. Includes Aranesp (darbepoetin alfa), Bumex (bumetanide), CellCept (mycophenolate mofetil).
  https://www.drugs.com/drug-interactions/amphotericin-b-liposomal.html
*  A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Intranasal Amphotericin B...
This phase II study investigated the safety and efficacy of amphotericin B in the complete resolution of key chronic sinusitis symptoms in patients with
  http://adisinsight.springer.com/trials/700245331
*  Amphotericin B from Streptomyces sp. BioReagent, suitable for cell culture, ~80% (HPLC) | Sigma-Aldrich
Sigma-Aldrich offers Sigma-A2411, Amphotericin B from Streptomyces sp. for your research needs. Find product specific information including CAS, MSDS, protocols and references.
  http://www.sigmaaldrich.com/catalog/product/sigma/a2411?lang=en®ion=US
*  Gentaur Molecular :PhytoTechnology Laboratories \ AMPHOTERICIN B \ A119-5G
Gentaur molecular products has all kinds of products like :search , PhytoTechnology Laboratories \ AMPHOTERICIN B \ A119-5G for more molecular products just contact us
  http://www.antibody-antibodies.com/product_det.php?id=1402177&supplier=search&name=AMPHOTERICIN%20B
*  share via email
In this randomized, double-blind, dose-ranging, multicenter trial, 84 patients with visceral leishmaniasis refractory to antimony therapy were administered liposomal amphotericin B (AmBisome) at cumulative doses of 3.75, 7.5, and 15.0 mg/kg for 5 consecutive days. Posttreatment apparent cure and definite cure were assessed at 2 weeks and 6 months after the end of therapy, respectively. Mild to moderate infusion-related fever and rigors were seen in 29 and 44% of patients, respectively. One patient each in the 3.75- and 7.5-mg groups had detectable parasites on splenic smear at posttreatment evaluation. At 6 months' follow-up, however, 2, 1, and 1 patients relapsed in the 3.75-, 7.5-, and 15.0-mg groups, resulting in definite cure rates of 89, 93, and 97%, respectively. There was no significant difference in the cure rates of the 3 groups. Low-dose liposomal amphotericin B given for 5 days can cure most patients with Indian kala-azar.
  http://www.ajtmh.org/content/journals/10.4269/ajtmh.2002.66.143
*  Biology-Online • View topic - The Fiber Disease
The in vitro and in vivo toxicities and activities of MS-8209, a new hydrosoluble amphotericin B (deoxycholate-amphotericin B [D-AmB]; Fungizone) derivative, were studied. In vitro, MS-8209 was less toxic than AmB against renal tubular cells in primary culture and less active against Candida albicans and Cryptococcus neoformans. However, at 10-fold the AmB concentration, MS-8209 in vitro antifungal activity paralleled that of AmB. Fifty-percent lethal doses of MS-8209 and D-AmB in OF1 noninfected mice were 26 and 2.3 mg/kg, respectively. Therapeutic efficacy of MS-8209 was assessed in murine candidiasis, cryptococcosis, and aspergillosis. In each model of infection, we determined the maximum tolerated dosages of MS-8209 and D-AmB, i.e., the dosage inducing less than 15% mortality due to toxicity; the efficacies of MS-8209 and D-AmB at their respective maximum tolerated dosages were compared. In candidiasis, MS-8209 (15 mg/kg) significantly ...
  http://www.biology-online.org/biology-forum/post-52553.html